Aynur Abdulla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aynur Abdulla has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Xianting Ding
Institute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai 200030, China
3 shared publications Haoni Yan
Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsHengxing Su
Department of Neurosurgery, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsYujie Shi
Department of Anesthesiology and Surgical Intensive Care Unit, Xinhua Hospital, School of Medicine and School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
2 shared publicationsAynur Abdulla
State Key Laboratory of Oncogenes and Related Genes, Institute for Personalized Medicine, School of Biomedical Engineering , Shanghai Jiao Tong University , Shanghai 200030 , China
1 shared publication- Azarmidokht Gholamipour-Shirazi
British Society of Rheology , Aberystwyth, Wales, UK
1 shared publication
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 12 (1) , 355
Black-hole system: in vivo continuous bioligand-assisted elimination of circulating tumor cells to prevent cancer recurrence and metastasis
In vivo continuous eradication of circulating tumor cells (CTCs) following chemotherapy represents a promising strategy to prevent cancer recurrence and metastasis, but remains a practical challenge. Here, we propose a bioligand-assisted in vivo therapy for dynamic check and hemo clearance of CTCs, termed the “Black-hole” system. Inspired by hemopurification, the Black-hole system integrates a peristaltic pump to maintain continuous blood flow, a functionalized microfluidic reservoir for CTCs sustained capture, and flexible tubing with needles for in vivo blood withdrawal and reinfusion. In this system, blood is drawn from the left carotid artery, passes through the microfluidic reservoir to selectively withhold CTCs, and is subsequently reinfused into the right jugular vein. Demonstration in a live tumor-bearing mouse model demonstrated the biosafety and efficacy of the system for single-pass, in vivo CTCs elimination. No significant morphological alterations were observed in major organs after the Black-hole system therapy. Notably, mice receiving the Black-hole therapy following paclitaxel chemotherapy exhibited a 50% survival rate, along with a 16.7% reduction in overall tumor recurrence. We expect the Black-hole system to become a safe and effective adjuvant therapy for postoperative cancer management.
- 2 November 2026
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 12 (1) , 355
Open AccessBlack-hole system: in vivo continuous bioligand-assisted elimination of circulating tumor cells to prevent cancer recurrence and metastasis
In vivo continuous eradication of circulating tumor cells (CTCs) following chemotherapy represents a promising strategy to prevent cancer recurrence and metastasis, but remains a practical challenge. Here, we propose a bioligand-assisted in vivo therapy for dynamic check and hemo clearance of CTCs, termed the “Black-hole” system. Inspired by hemopurification, the Black-hole system integrates a peristaltic pump to maintain continuous blood flow, a functionalized microfluidic reservoir for CTCs sustained capture, and flexible tubing with needles for in vivo blood withdrawal and reinfusion. In this system, blood is drawn from the left carotid artery, passes through the microfluidic reservoir to selectively withhold CTCs, and is subsequently reinfused into the right jugular vein. Demonstration in a live tumor-bearing mouse model demonstrated the biosafety and efficacy of the system for single-pass, in vivo CTCs elimination. No significant morphological alterations were observed in major organs after the Black-hole system therapy. Notably, mice receiving the Black-hole therapy following paclitaxel chemotherapy exhibited a 50% survival rate, along with a 16.7% reduction in overall tumor recurrence. We expect the Black-hole system to become a safe and effective adjuvant therapy for postoperative cancer management.
- Open Access
- 5 January 2026
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 12 (1) , 11
ASM-chip: an antibody-modified size-screening microfluidic chip for high-efficiency circulating glioma cell isolation and clinical application
Peripheral blood circulating glioma cells (CGCs) are crucial for glioma screening, prognostic evaluation, and diagnostic applications. However, reliable methods for efficient CGCs capture and comprehensive clinical evaluation on whether CGCs could faithfully represent complicated heavy equipment (such as MRI) remain insufficiently explored. Here, we present an antibody modification and size screening-based microfluidic (ASM) chip for effectively capturing CGCs, specifically designed for potential clinical translational applications. The ASM chip consists of one inlet, three outlets, one white blood cell clearance area, and one CGC capture area. The performance of the chip was optimized with two typical cell subtypes, namely SU-DHL-4 (to simulate leukocytes) and U251MG-ZsGreen (to simulate CGCs), and the capture rate reached more than 96% at a flow rate of 1.2 mL/h. In real-life applications, CGCs (1–25/mL) were detected in 21 out of 35 glioma patients. We found that the number of CGCs was relatively high in patients with wild-type IDH1 and was positively correlated with Ki67 expression (p = 0.026). The enrichment of CGC was correlated with neutrophils (p = 0.041) and heparin-binding protein (p = 0.0064), suggesting neutrophil-mediated metastasis. Radiomics linked a higher presence of CGCs with larger tumors, severe necrosis, and extensive edema, suggesting a poor prognosis for patients. The ASM chip can effectively capture and quantify CGCs for guiding the diagnosis and predicting the potential prognosis of clinical glioma patients.
- 5 January 2026
- Published by Springer Nature in Microsystems & Nanoengineering
- Vol. 12 (1) , 11
Open AccessASM-chip: an antibody-modified size-screening microfluidic chip for high-efficiency circulating glioma cell isolation and clinical application
Peripheral blood circulating glioma cells (CGCs) are crucial for glioma screening, prognostic evaluation, and diagnostic applications. However, reliable methods for efficient CGCs capture and comprehensive clinical evaluation on whether CGCs could faithfully represent complicated heavy equipment (such as MRI) remain insufficiently explored. Here, we present an antibody modification and size screening-based microfluidic (ASM) chip for effectively capturing CGCs, specifically designed for potential clinical translational applications. The ASM chip consists of one inlet, three outlets, one white blood cell clearance area, and one CGC capture area. The performance of the chip was optimized with two typical cell subtypes, namely SU-DHL-4 (to simulate leukocytes) and U251MG-ZsGreen (to simulate CGCs), and the capture rate reached more than 96% at a flow rate of 1.2 mL/h. In real-life applications, CGCs (1–25/mL) were detected in 21 out of 35 glioma patients. We found that the number of CGCs was relatively high in patients with wild-type IDH1 and was positively correlated with Ki67 expression (p = 0.026). The enrichment of CGC was correlated with neutrophils (p = 0.041) and heparin-binding protein (p = 0.0064), suggesting neutrophil-mediated metastasis. Radiomics linked a higher presence of CGCs with larger tumors, severe necrosis, and extensive edema, suggesting a poor prognosis for patients. The ASM chip can effectively capture and quantify CGCs for guiding the diagnosis and predicting the potential prognosis of clinical glioma patients.
- 1 December 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (40) , 8433-8450
Application of Microfluidics in Single-cell Manipulation, Omics and Drug Development
Background: Cell heterogeneity exists among different tissues even in the same type of cells. Cell heterogeneity leads to a difference in cell size, functions, biological activity, and for cancer cells it causes different drug responses and resistance. Meanwhile, microfluidics is a promising tool for single-cell research to reveal cell heterogeneity. Method: Through literature research conducted over the past ten years on microfluidics, we summarize and introduce the application of microfluidics in single-cell separation and manipulation, featuring techniques such as acoustic manipulation, optical manipulation, single-cell trapping, and patterning, as well as single-cell omics including single-cell genomics, single-cell transcriptomics, single-cell proteome, single-cell metabolome, and drug development. Results: Microfluidics is a flexible, precise tool, and it is easy to integrate with different functions. Firstly, it can be used as an important tool to separate rare but important cells according to the cell`s biological or physical properties. Secondly, microfluidics can provide the possibility of single-cell omics. Thirdly, microfluidics can be used in drug development, specifically in drug delivery and drug combination. Meanwhile, droplet microfluidics has gradually become the most powerful tool to encapsulate single-cells with other reagents for DNA, RNA, or protein analysis. Conclusion: Microfluidics is a robust platform technology which is able to accomplish rare cell separation, efficient single-cell omics analysis and provide a platform for drug development and drug delivery.
- 1 December 2021
- Published by Bentham Science Publishers Ltd. in Current Medicinal Chemistry
- Vol. 28 (40) , 8433-8450
Application of Microfluidics in Single-cell Manipulation, Omics and Drug Development
Background: Cell heterogeneity exists among different tissues even in the same type of cells. Cell heterogeneity leads to a difference in cell size, functions, biological activity, and for cancer cells it causes different drug responses and resistance. Meanwhile, microfluidics is a promising tool for single-cell research to reveal cell heterogeneity. Method: Through literature research conducted over the past ten years on microfluidics, we summarize and introduce the application of microfluidics in single-cell separation and manipulation, featuring techniques such as acoustic manipulation, optical manipulation, single-cell trapping, and patterning, as well as single-cell omics including single-cell genomics, single-cell transcriptomics, single-cell proteome, single-cell metabolome, and drug development. Results: Microfluidics is a flexible, precise tool, and it is easy to integrate with different functions. Firstly, it can be used as an important tool to separate rare but important cells according to the cell`s biological or physical properties. Secondly, microfluidics can provide the possibility of single-cell omics. Thirdly, microfluidics can be used in drug development, specifically in drug delivery and drug combination. Meanwhile, droplet microfluidics has gradually become the most powerful tool to encapsulate single-cells with other reagents for DNA, RNA, or protein analysis. Conclusion: Microfluidics is a robust platform technology which is able to accomplish rare cell separation, efficient single-cell omics analysis and provide a platform for drug development and drug delivery.
- 14 March 2018
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 90 (7) , 4397-4405
High-Throughput Isolation of Circulating Tumor Cells Using Cascaded Inertial Focusing Microfluidic Channel
Circulating tumor cells (CTCs) are rare cells that detach from primary or metastasis tumor and flow into the blood stream. Intact and viable tumor cells are needed for genetic characterization of CTCs, new drug development, and other research. Although separation of CTCs using spiral channel with two outlets has been reported, few literatures demonstrated simultaneous isolation of different types of CTCs from human blood using cascaded inertial focusing microfluidic channel. Herein, we introduce a cascaded microfluidic device consisting of two spiral channels and one zigzag channel designed with different fluid fields, including lift force, Dean drag force, and centrifugal force. Both red blood cells (RBCs)-lysed human blood spiked with CTCs and 1:50 diluted human whole blood spiked with CTCs were tested on the presented chip. This chip successfully separated RBCs, white blood cells (WBCs), and two different types of tumor cells (human lung cancer cells (A549) and human breast cancer cells (MCF-7)) simultaneously based on their physical properties. 80.75% of A549 and 73.75% of MCF-7 were faithfully separated from human whole blood. Furthermore, CTCs gathered from outlets could propagate and remained intact. The cell viability of A549 and MCF-7 were 95% and 98%, respectively. The entire separating process for CTCs from blood cells could be finished within 20 minutes.The cascaded microfluidic device introduced in this study serves as a novel platform for simultaneous isolation of multiple types of CTCs from patient blood.
- 14 March 2018
- Published by American Chemical Society (ACS) in Analytical Chemistry
- Vol. 90 (7) , 4397-4405
High-Throughput Isolation of Circulating Tumor Cells Using Cascaded Inertial Focusing Microfluidic Channel
Circulating tumor cells (CTCs) are rare cells that detach from primary or metastasis tumor and flow into the blood stream. Intact and viable tumor cells are needed for genetic characterization of CTCs, new drug development, and other research. Although separation of CTCs using spiral channel with two outlets has been reported, few literatures demonstrated simultaneous isolation of different types of CTCs from human blood using cascaded inertial focusing microfluidic channel. Herein, we introduce a cascaded microfluidic device consisting of two spiral channels and one zigzag channel designed with different fluid fields, including lift force, Dean drag force, and centrifugal force. Both red blood cells (RBCs)-lysed human blood spiked with CTCs and 1:50 diluted human whole blood spiked with CTCs were tested on the presented chip. This chip successfully separated RBCs, white blood cells (WBCs), and two different types of tumor cells (human lung cancer cells (A549) and human breast cancer cells (MCF-7)) simultaneously based on their physical properties. 80.75% of A549 and 73.75% of MCF-7 were faithfully separated from human whole blood. Furthermore, CTCs gathered from outlets could propagate and remained intact. The cell viability of A549 and MCF-7 were 95% and 98%, respectively. The entire separating process for CTCs from blood cells could be finished within 20 minutes.The cascaded microfluidic device introduced in this study serves as a novel platform for simultaneous isolation of multiple types of CTCs from patient blood.